BioCurate CEO Appointed

An outstanding industry leader with exceptional national and global experience in successfully propelling important biomedical discoveries out of the lab and into the market has been appointed inaugural CEO of BioCurate Pty Ltd.  This AUD $80 million venture was launched last year by Monash University and the University of Melbourne and supported by the Victorian Government. The appointment is the result of an extensive international and national search.

Chair of BioCurate and former Premier of Victoria (2007-2010) the Hon. John Brumby AO today announced the appointment of Dr C. Glenn Begley as the CEO. Dr Begley has held senior academic positions in Australia, and worked in small biotech and large pharmaceutical companies. Most recently he was the Chief Scientific Officer of a privately-funded biotech company Akriveia Therapeutics, in California.

“I’m delighted to welcome Dr Begley back to Australia and into a pivotal role within this new enterprise,” Mr. Brumby said.

“Dr Begley brings an extraordinary combination of commercial, academic and clinical insight to this significant venture – the first of this scope and scale in Australia – whose ambition is to unlock the exceptional research capabilities of the University of Melbourne and Monash University and their partners in hospitals, medical institutes and industry, enabling significant new discoveries to be translated more rapidly into new medicines. The social and economic implications for Victoria and Australia are profound.”

A clinical haematologist and medical oncologist, whose academic and commercial roles include board level and senior positions in Australia, the USA and the UK, Dr Begley said he was looking forward to playing a leading role in shaping the strategic direction and operations of BioCurate Pty Ltd:

“I am delighted to be joining BioCurate at this important moment in its development,” Dr Begley said.

“Now more than ever it’s critical that important medical discoveries make it from the lab into new medicines and that the clinical and commercial benefits accrue to Australia. I am confident that BioCurate, building on the combined research strength of these two outstanding universities will ensure transformational drug candidates become a reality.”

Dr Begley will commence his appointment on 22 May 2017.

Read more here


News & opinion

Member Directory